Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 11/20 | 0.39 |
| ▸ | CA2 | P00918 | 11/20 | 0.39 |
| ▸ | MMP1 | P03956 | 4/20 | 0.39 |
| ▸ | MMP2 | P08253 | 4/20 | 0.39 |
| ▸ | MMP9 | P14780 | 4/20 | 0.39 |
| ▸ | MMP8 | P22894 | 4/20 | 0.39 |
| ▸ | MMP13 | P45452 | 4/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28498811 | 0.77 | CA1 (0.41) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL17725466 | 0.75 | SMN1; SMN2 (0.43) | CA1CA2HSD11B1CA9 | |
| Tert-Butylbenzene SCHEMBL28573150 | 0.74 | CA1 (0.38) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL449214 | 0.73 | CA1 (0.38) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL27617782 | 0.72 | HSD11B1 (0.41) | HSD11B1PPARGPPARACYP2C19 | |
| SCHEMBL6479936 | 0.70 | CA2 (0.45) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL31495940 | 0.70 | KMT2A (0.42) | PPARGPPARACYP2C19 | |
| SCHEMBL379586 | 0.69 | CA1 (0.38) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL28364160 | 0.69 | CXCR2 (0.42) | HSD11B1PPARGPPARACYP2C9CYP2C19 | |
| SCHEMBL6900759 | 0.68 | CA2 (0.46) | CA1CA2MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2229942-B1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | DOMPE SPA (IT) | 2012-08-29 | — | — | EP | disclosed |
| US-8063242-B2 | for treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bollous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis; prevention and treatment of damages caused by ischemia and reperfusion | DOMPE PHA.R.MA S.P.A. (IT) | 2011-11-22 | — | — | US | disclosed |
| EP-2229942-A1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | Dompe S.p.A. (IT) | 2010-09-22 | — | — | EP | disclosed |
| US-20050038119-A1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2005-02-17 | — | — | US | disclosed |
| EP-1455773-A1 | 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompé S.P.A. (IT) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003043625-A1 | 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE S.P.A. (IT) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038119-A1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | CXCR2, FPR1, CCR2 | CA1 2561/4885CA2 1978/4885MMP1 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.